Nimbus

Oct 14, 2020

Nimbus Therapeutics宣布从新投资者获得6000万美元私人融资以推进扩大的管道 本文共1277个字，阅读需4分钟 Leading life science investors RA Capital Management and BVF Partners L.P. join Nimbus investor baseCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the close of a $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P. (“RA” and “BVF”, respectively). The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 (TYK2) inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 (HPK1) inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.“Today’s financing evidences the remarkable success of our structure-based drug discovery approach and the exciting data our pipeline has generated,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “This financing also defines a pathway for our future, and while we could not welcome all the investors with interest in Nimbus into this round, we expect with continued success to build on this financing by bringing on additional new investment in 2021.”“Nimbus’ compelling TYK2 clinical data clearly positions us for a Phase 2b trial, which will generate data on the same endpoints as BMS’ TYK2 program,” said Bruce Booth, D.Phil., co-founder and Chairman of the Board of Nimbus. “We are fortunate to have RA and BVF join Nimbus, and we welcome Laura Stoppel from RA to the Board.”“We’re proud to join Nimbus’ circle of investors and to lead this most recent financing round,” said Peter Kolchinsky, Ph.D., a founder and Managing Partner of RA Capital Management. “We see tremendous potential for Nimbus’ lead program, one of only two clinical allosteric approaches to TYK2 inhibition, and for the company’s newly added preclinical programs to address important therapeutic needs in oncology, immunology, and metabolism.”About Nimbus TherapeuticsNimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005126/en/Lisa Raffensperger, (617) 903-8783Ten Bridge Communicationslisa@tenbridgecommunications.comSource: Nimbus TherapeuticsView this news release online at:http://www.businesswire.com/news/home/20201014005126/en 领先的生命科学投资者RA Capital Management和BVF Partners L.P。加入Nimbus投资者基础美国马萨诸塞州，剑桥----（商业热线）----一家通过基于结构的药物发现和开发来设计突破性药物的生物技术公司Nimbus Therapeutics今天宣布，生命科学投资者RA Capital Management和BVF Partners L.P.完成了一轮6000万美元的私人融资。（分别为“RA”和“BVF”）。这些资金支持Nimbus公司的1期变构酪氨酸激酶2(TYK2)抑制剂明年初加速进入2期，造血祖细胞激酶1(HPK1)抑制剂明年进入临床，以及推进其临床前新药组合。Nimbus公司首席执行官Jeb Keiper，M.S.，MBA说:“今天的融资证明了我们基于结构的药物发现方法的显著成功，以及我们的管道所产生的激动人心的数据。“这笔融资也为我们的未来指明了一条道路，虽然我们无法欢迎所有对Nimbus感兴趣的投资者参与这一轮融资，但我们希望在持续成功的情况下，通过在2021年带来更多新的投资，在此次融资的基础上再接再厉。”Nimbus公司联合创始人兼董事会主席Bruce Booth博士说:“Nimbus公司令人信服的TYK2临床数据为我们提供了一个2B期试验，该试验将产生与BMS公司TYK2项目相同终点的数据。“我们很幸运有RA和BVF加入Nimbus，我们欢迎来自RA的劳拉·斯托佩尔进入董事会。”RA Capital Management的创始人兼管理合伙人Peter Kolchinsky博士说:“我们很荣幸加入Nimbus的投资者圈子，并领导最近一轮融资。我们认为，Nimbus公司的lead项目（仅有的两种抑制TYK2的临床变构方法之一）以及该公司新增加的临床前项目具有巨大的潜力，以满足肿瘤学，免疫学和新陈代谢方面的重要治疗需求。“关于Nimbus TherapeuticsNimbus Therapeutics设计突破性药物。利用其强大的基于结构的药物发现引擎，Nimbus设计了针对蛋白质的强效和选择性小分子化合物，这些蛋白质已知是高度流行的人类疾病的基本病理驱动因素，而其他药物制造商已证明难以解决这些蛋白质。该公司的有限责任公司/附属公司架构使多样化和协同的伙伴关系能够提供突破性的药物。Nimbus公司总部设在马萨诸塞州剑桥。www.nimbustx.com。在businesswire.com上查看源代码版本:https://www.businesswire.com/news/home/20201014005126/en/Lisa Raffensberger，（617）903-8783十桥通信电子邮件:lisa@tenbridgecommunications.com资料来源:Nimbus Therapeutics在线查看此新闻稿:http://www.businesswire.com/news/home/20201014005126/en 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。